Last updated: April 28, 2026
Definity (Perflutren Lipid Microsphere) Clinical Trials Update, Market Analysis, and Projection
What is Definity and how is it used clinically?
Definity is a contrast agent for echocardiography. The labeled use is to improve cardiac ultrasound image quality by opacifying the left ventricular cavity in patients with suboptimal echocardiograms. It is delivered as an injectable microsphere formulation intended for ultrasound imaging.
What clinical trials exist and what is the latest update?
Definity’s clinical development is mature and the current landscape is dominated by post-approval use rather than new phase programs. The Definity program is integrated with the perflutren lipid microsphere class and earlier pivotal evidence established efficacy for left ventricular opacification with improved diagnostic image quality versus controls.
No current, clearly identifiable new late-stage (Phase 3 or pivotal) Definity-specific trials were identified from the publicly indexed sources cited below. Active research activity around perflutren-based agents continues, but it is not represented here as an identifiable, ongoing Definity-specific Phase 3 program.
Clinical trial evidence base (pivotal and supporting):
- Pivotal efficacy in left ventricular opacification and image quality improvement was used to support approval and clinical adoption.
- The evidentiary package used dose/contrast performance, image quality endpoints, and safety monitoring aligned with echocardiography labeling requirements.
Sources: FDA labeling and historical approval package reflected in labeling content and summary references. [1]
What are the main competitive and substitution dynamics?
Definity’s category is competitive with other ultrasound contrast agents. Substitution dynamics tend to pivot on:
- Reimbursement and bundled imaging workflows.
- Site preference and formulary access.
- Per-dose economics tied to vial size, dosing frequency, and procedural throughput.
- Safety and tolerability profile as reflected in labeling and institutional policies.
Key class alternatives include perflutren-based agents and other echocardiography contrast options with different dosing, kinetics, and labeling constraints. The market’s share distribution is strongly influenced by procurement contracts and guideline adherence.
Who are the key stakeholders in the Definity market?
- Manufacturer/marketed holder: The brand is marketed in the US under the Definity name and is tied to the US label and distribution ecosystem defined by the NDA holder and its commercial partners. [1]
- Providers: Hospital cardiology labs, echocardiography centers, and outpatient imaging practices using contrast-enhanced echocardiography in routine and referral settings.
- Payors: Commercial and government payors shaping access through coverage policies and hospital reimbursement rules.
What does the current label imply for penetration and demand?
Labeling constraints and eligibility influence addressable demand. The Definity label defines patient selection and operational rules for administration and monitoring, affecting:
- Routine adoption in patients with technically limited windows.
- Use in stress echo and other procedural variants where contrast improves diagnostic confidence.
Practical label-driven demand levers
- Patient volume with suboptimal baseline windows in cardiology workstreams.
- Protocol adoption where contrast is used earlier rather than as a last resort.
- Institutional contrast utilization policies and training.
(Operational label requirements are described in the US prescribing information.) [1]
Market Analysis: Size, Drivers, and Share Controls
What are the demand drivers for echocardiography contrast agents?
Demand for ultrasound contrast agents is driven by structural factors in cardiovascular imaging:
- High volume of echocardiography procedures in cardiology and hospital settings.
- Clinician preference for image interpretability and diagnostic confidence.
- Increased use of echocardiography for outcomes tracking, valvular assessment, cardiomyopathy workup, and heart failure monitoring.
What does Definity’s competitive positioning look like?
Definity is positioned in a mature contrast market. Key market constraints:
- Competitive pressure from other contrast agents and lifecycle management (formulary changes, pricing, contracting).
- Potential for generics or authorized equivalents depending on IP and regulatory pathways in the relevant jurisdictions.
- Procurement-based bargaining power of health systems and imaging networks.
How do formulary and reimbursement affect revenue?
Reimbursement and formulary access are the dominant short-term determinants of unit sales. Contrast use often sits inside broader diagnostic reimbursement frameworks where:
- Hospital billing and internal charge capture can drive uptake.
- Standalone pass-through pricing and bundled imaging claims affect payor acceptance.
- Coverage determinations can require documented “suboptimal image quality,” limiting automatic use.
These mechanisms shape adoption curves across regions and hospital networks, with uptake faster in sites with established echocardiography contrast protocols.
Projections: Revenue Outlook and Volume Trajectory
What is the projection framework for Definity?
For a mature branded contrast agent, projections should be modeled on:
- Procedure volume growth in echocardiography (units of imaging).
- Contrast utilization rate growth (penetration changes from protocol adoption).
- Unit consumption per patient (dose and imaging workflow).
- Price and net revenue (contracting, discounting, reimbursement friction).
- Competitive and substitution effects (agent switching by formulary).
Definity’s forward outlook is best expressed as a continuation of market share stability with incremental penetration where contrast is used to improve diagnostic utility, offset by price pressure from competition.
Market projection: scenario-based directional outcomes
Because publicly indexed sources here do not provide Definity-specific forecasts with numeric revenue for 2025 to 2035, the only defensible projection statement based on the cited data is directional:
Directional projection (2026 onward)
- Base case: stable-to-moderate growth tied to echocardiography procedure growth and gradual penetration of contrast protocols, tempered by contracting and substitution.
- Downside case: faster share erosion if competing agents secure formulary position or if pricing pressure intensifies.
- Upside case: higher adoption in high-volume cardiology networks where contrast is used earlier for suboptimal windows.
This matches the mature, label-driven nature of the product and the fact that its pivotal evidence is already established. [1]
Regulatory and Lifecycle Signals
Is there any current regulatory activity likely to change the product outlook?
The defining regulatory “signal” in the Definity landscape is the stability of the US prescribing information and clinical use patterns already incorporated into current labeling.
No specific, newly announced, Definity-only regulatory accelerations are captured in the cited sources below.
Key Takeaways
- Definity is an established echocardiography contrast agent with clinical utility centered on left ventricular opacification and improved imaging in patients with suboptimal echocardiograms. [1]
- The current clinical trial landscape is not characterized here by new Definity-specific late-stage pivotal trials; the evidence base is mature and tied to the US label. [1]
- Market demand is structurally tied to cardiovascular imaging volume and contrast utilization rates that depend on hospital protocols, formulary access, and reimbursement mechanics.
- Projections for Definity should be modeled around penetration and price netbacks rather than trial-driven step changes, given the mature lifecycle of the product and the label-defined use case. [1]
FAQs
-
What clinical endpoint defines Definity’s value?
Improved echocardiography image quality via left ventricular cavity opacification in patients with suboptimal baseline imaging. [1]
-
What patient group drives Definity demand most?
Patients who have technically limited echocardiograms where contrast is needed to make images interpretable for diagnostic decision-making. [1]
-
Is Definity in a late-stage clinical development cycle?
The cited public evidence reflects a mature product with an established pivotal evidence base rather than an identifiable, ongoing Definity-specific Phase 3 program. [1]
-
What most influences Definity revenue over the next few years?
Net pricing from hospital contracting, formulary access, and contrast utilization rates driven by echocardiography workflow protocols. [1]
-
How does competition likely affect Definity’s forecast?
Share stability is vulnerable to substitution based on formulary preference and pricing, since the product class competes within ultrasound contrast agent use cases. [1]
References
[1] U.S. Food and Drug Administration. (n.d.). Definity (perflutren lipid microsphere) prescribing information / label. FDA. https://www.accessdata.fda.gov (accessed via FDA label records).
